While the focus is on Thalidomide, Celgene has other compelling reasons to be a very good investment. Investors should understand this company and the various technologies that will be comercialized in the future. I, for one, believe that the Board of Directors of this company has the capability to realize all of the potential Celgene will demonstrate.
Absolutely. Thalidomide now will help Celg hold the market until its Thalidomide analoge gets approval. The real money in this Company is 2-4 years down the road. The time in between will be profitable too!